Economic and social impact of migraine

QJM: An International Journal of Medicine

Volumn 89, Issue 1, 1996, Pages 77-84

  Clarke, C E ^a   MacMillan, L ^b   Sondhi, S ^b   Wells, N E J ^b  

^a HULL ROYAL INFIRMARY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ARTICLE; COST; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIOECONOMICS; WORK;

EID: 0030024968     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.qjmed.a030141     Document Type: Article

References (22)

1. Cull RE, Wells NE, Moicevich ML. The economic cost of migraine. Br J Med Econ 1992; 2:103-15.
2. Office of Health Economics. Migraine London, OHI, 1991.
3. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20:131-7.
4. Osterhaus JT, Gutterman DL, Plachetka JR. Health care resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2:67-76.
5. International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (suppl 7):19-28.
6. Stewart WF, Lipton RB. Migraine headache; epidemiology and health care utilisation. Cephalalgia 1993; 13 (suppl 12):41-6.
7. Green JE. A survey of migraine in England 1975-1976. Headache 1977; 17:67-8.
8. Honkasalo ML, Kaprio J, Heikkila K, Sillanpaa M, Koskenvuo M. A population-based survey of headache and migraine in 22,809 adults. Headache 1993; 33:403-12.
9. Strang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33:29-35.
10. Winnem J. Prevalence of adult migraine in general practice. Cephalalgia 1992; 12:300-3.
11. Tom T, Brody M, Valabhji A, Turner L, Molgaard C, Rothrock J. Validation of a new instrument for determining migraine prevalence. Neurology 1994; 44:925-8.
12. Rasmussen BK, Jensen RJ, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 1991; 11:129-34.
13. Michel P, Dartigues JF, Henry P, et al. Validity of the International Headache Society criteria for migraine. Neuroepidemiology 1993; 12:51-7.
14. Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among headache diagnoses? Analysis using the Medical Outcomes Study Instrument. Headache 1994; 34:143-7.
15. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34:337-43.
16. Dahlof C. Assessment of health-related quality of life in migraine. Cephalalgia 1993; 13:233-7.
17. Editorial. Absenteeism - How firms can make up for lost time. CBI News 1994; October:36-7.
18. The oral sumatriptan dose-defining study group. Sumatriptan - an oral dose-defining study. Eur Neurol 1991; 31:300-5.
19. The multinational oral sumatriptan and cafergot comparative study group. A randomised, double-blind comparison of sumatriptan and cafergot in the actute treatment of migraine. Eur Neurol 1991; 31:314-22.
20. Lipton RB, Stewart WF. Migraine in the United States. Neurology 1993; 43 (suppl 3):S6-S10.
21. Devlin J, Michaelson J. Personal communication.
22. Adelman JU, Sharfman M, Johnson RJ, Miller DW, Clements BD, Paid DG, Boshkoff MR, Gutterman DL. Impact of oral sumatriptan on health-related quality of life and productivity in health care professionals with migraine: An interim analysis. Proceedings American College of Clinical Pharmacy 1995; in Press.